Lunai Bioworks regains Nasdaq minimum bid price compliance; faces 1-year monitoring

Lunai Bioworks Inc.

Nasdaq confirmed Lunai Bioworks regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Company met terms set by Nasdaq Hearings Panel decisions dated April 20, 2026 and May 12, 2026.
Mandatory Panel monitor imposed for one year; no compliance plan or cure period if bid price drops again.
If non-compliant during monitor, Nasdaq will issue delist determination; company may request new hearing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.